Merck's $800 Million Investment In Singapore Aims To Produce Returns Elsewhere
This article was originally published in PharmAsia News
Executive SummarySINGAPORE - Merck & Co. Inc. has committed to manufacturing and research investments in Singapore totaling more than $800 million to meet the ever increasing demand in nearby emerging markets
You may also be interested in...
Seeing Is Believing: GSK Pledges To Upgrade Key Antibiotics Plant As Witty Hosts Q3 Call From Singapore
During a celebration to mark GSK’s 40th year in Singapore, CEO Andrew Witty announces new investments in work-horse manufacturing plants and reaffirms openness to share patient data from clinical studies.
Novartis plans to build a new center of excellence for biotechnology manufacturing costing more than $500 million, as it looks to leverage Singapore’s skilled labor force and proximity to growth markets like China.
The company will pursue a Phase III trial for acute otitis media with a compound that is partnered with Novartis’ Alcon.